Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 11/20 | 0.39 |
| ▸ | GSK3A | P49840 | 9/20 | 0.39 |
| ▸ | SSTR2 | P30874 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 4/20 | 0.36 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | CHUK | O15111 | 1/20 | 0.34 |
| ▸ | CTSA | P10619 | 1/20 | 0.34 |
| ▸ | KDM5A | P29375 | 1/20 | 0.34 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.34 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.34 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20621861 | 0.82 | NPSR1 (0.52) | MAPTMEN1ALDH1A1LMNAKMT2A | |
| SCHEMBL20599779 | 0.77 | MEN1 (0.39) | GSK3BGSK3AMAPTMEN1LMNA | |
| SCHEMBL20599894 | 0.74 | KCNA5 (0.42) | MAPTKCNA5MEN1ALDH1A1LMNA | |
| SCHEMBL20600158 | 0.70 | CCNC (0.40) | MAPTKMT2AKDM4C | |
| SCHEMBL20599878 | 0.69 | MEN1 (0.39) | MAPTMEN1LMNAKMT2AROCK2 | |
| SCHEMBL11804826 | 0.66 | LMNA (0.52) | MAPTMEN1ALDH1A1LMNAKMT2A | |
| SCHEMBL30824201 | 0.65 | MDM2 (0.47) | MEN1ALDH1A1LMNAKMT2A | |
| SCHEMBL28373543 | 0.64 | GSK3B (0.35) | GSK3BGSK3ASSTR2KCNH2MAPT | |
| SCHEMBL18984723 | 0.64 | MAPT (0.52) | MAPTMEN1ALDH1A1LMNAKMT2A | |
| SCHEMBL9433809 | 0.64 | GPBAR1 (0.36) | MAPTKCNA5MEN1ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3615527-B1 | NEW AZAQUINOLINE DERIVATIVES | ELANCO ANIMAL HEALTH GMBH (DE) | 2024-03-06 | — | — | EP | disclosed |
| US-11485733-B2 | Azaquinoline derivatives | BAYER ANIMAL HEALTH GMBH (DE) | 2022-11-01 | — | — | US | disclosed |
| US-20200131175-A1 | NEW AZAQUINOLINE DERIVATIVES | BAYER ANIMAL HEALTH GMBH (DE) | 2020-04-30 | — | — | US | disclosed |
| EP-3615527-A1 | NEW AZAQUINOLINE DERIVATIVES | Bayer Animal Health GmbH (DE) | 2020-03-04 | — | — | EP | disclosed |
| WO-2019002132-A1 | NEW AZAQUINOLINE DERIVATIVES | BAYER ANIMAL HEALTH GMBH (DE) | 2019-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200131175-A1 | NEW AZAQUINOLINE DERIVATIVES | RECQL, H1-5, CHRM1 | GSK3B 4049/4885GSK3A 3742/4885SSTR2 1554/4885 |
| US-11485733-B2 | Azaquinoline derivatives | RECQL, H1-5, H1-3 | GSK3B 3529/4885GSK3A 3134/4885SSTR2 1365/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.